FILTER
FILTERED INTERVIEW RESULTS
Federico De Simone
CHAIRMAN, DE SIMONE GROUP
De Simone is a Ghanaian indigenous company that started operating in 1964 and has since expanded into various sectors such as power, mining and oil & gas, and currently operates in Ghana, Ivory Coast, Burkina Faso, Nigeria, Liberia, Mali and Guinea.
Guido Brusco
EVP WEST AFRICA, ENI
The Italian E&P company maintains strong levels of activity in Africa.
Eric Asubonteng
MANAGING DIRECTOR, ANGLOGOLD ASHANTI
AngloGold Ashanti speaks about its Obuasi mine in Ghana.
Baffour Yeboah & David Koomson
AFTER MARKET LEADER & ADOE REGIONAL LEADER, EAST AND CROSS BORDER TERRITORY, CUMMINS GHANA
Cummins touts its focus on customer service as a differentiator for the company’s business in Ghana.
Ernest Nsiah
MANAGING DIRECTOR, EDM AFRICAN RESOURCES
EDM African Resources is a start-up in Ghana with big ambitions to service the West Africa mining industry.
Peter Quarm
DIRECTOR, DUTYLEX
Dutylex is a Ghana-based supplier of lubricants for the West Africa mining industry.
Paul Alexander
MANAGING DIRECTOR, STORM PROCUREMENT
Storm Procurement purchases goods from 27 different countries across four continents to support miners’ access to high quality supplies.
Soraya Anglow
CHIEF EXECUTIVE OFFICER, GREENLINE LOGISTICS
Greenline Logistics celebrates its 25th anniversary milestone in November 2019.
Georgette Barnes
PRESIDENT, WOMEN IN MINING
WIM Ghana is looking for ways make careers in mining more attractive to women.
Bashir Amed
VICE PRESIDENT OF PRODUCTION & DEVELOPMENT, ASANTE GOLD
Asante Gold discusses how the SMD technique will make its Kubi gold project more cost-efficient.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
